European House Dust Mite (Der p 2) IgE Test · Blood

If you wake up congested, wheeze in dusty rooms, or live with stubborn eczema or asthma, dust mites are one of the most common hidden drivers. This blood test measures IgE (a type of immune antibody) directed at Der p 2, a major protein from the European house dust mite (Dermatophagoides pteronyssinus), and helps clarify whether your immune system has truly become allergic to it.

Knowing your Der p 2 IgE level matters because it can help separate a generic positive mite test from a genuine, clinically relevant allergy. People who react to Der p 2 are more likely to have asthma, more likely to react when their airways are challenged with mite extract, and more likely to benefit from targeted allergy treatment.

What This Test Actually Measures

Der p 2 (Dermatophagoides pteronyssinus allergen 2) is one of two dominant proteins found in European house dust mite waste and bodies. When you inhale these proteins, your immune system can make IgE antibodies that recognize them. Those antibodies sit on immune cells called mast cells. The next time you breathe in mite particles, the antibodies trigger the release of histamine and other chemicals that drive sneezing, itching, congestion, and airway tightening.

The blood test counts how much Der p 2 specific IgE is circulating. Together with Der p 1 (the other group 1 major allergen), Der p 2 accounts for a large share of all the IgE binding to whole dust mite extract in mite allergic people. Across cohorts in China and Europe, a majority of mite sensitized patients carry Der p 2 IgE, and in one Italian multicenter study the average Der p 2 IgE level among allergic patients was around 24 kU/L.

Why It Matters for Asthma

Der p 2 IgE is one of the strongest blood signals that dust mite allergy is driving real lung inflammation, not just a positive number on a panel. In one study of adults who underwent a mite bronchial challenge (where mite extract is inhaled under medical supervision), nearly all participants who had an immediate asthmatic response were positive for Der p 2 IgE. The test predicted that asthmatic response with high accuracy.

Across cohorts, people positive for both Der p 1 and Der p 2 have the highest rates of asthma among rhinitis sufferers, and children with asthma carry higher mite component IgE (including Der p 2) than non asthmatic children. Broad sensitization across multiple mite components, with Der p 2 in the mix, tracks with more severe disease and poorer asthma control.

Allergic Rhinitis

Year round stuffy nose, sneezing, and post nasal drip in temperate climates is often a mite story. In Chinese rhinitis patients, roughly two thirds were Der p 2 positive, and Der p 1 and Der p 2 were the leading sensitizing components. Patients who carry IgE to both Der p 1 and Der p 2 tend to have more severe combined nasal and chest symptoms than those with isolated sensitization.

Atopic Dermatitis

In adults with severe, type 2 driven eczema (a form of atopic dermatitis with very high IgE and eosinophils), Der p 2 is one of the most frequently recognized mite molecules, present in a large majority of patients in high exposure climates. It is not a cause of the rash by itself, but high Der p 2 IgE tends to mark people whose skin disease sits on top of a broader, mite driven allergic phenotype that also includes airway disease.

What Standard Mite Testing Misses

A traditional mite test (skin prick or extract IgE) reports whether you react to a soup of dozens of mite proteins. That is sensitive, but it cannot tell you which specific molecule is driving your immune response, and skin tests verified against nasal challenge have a positive predictive value of only about 70 percent.

Component testing for Der p 2 (and Der p 1) is more specific for genuine mite allergy and correlates better with bronchial reactivity than crude extract. In one analysis, IgE to Der p extract correlated strongly with Der p 1 and Der p 2, and most extract sensitized patients tested positive for Der p 1 or Der p 2. A meta analysis pooling seven studies and over 1,000 subjects concluded that Der p 1 or Der p 2 IgE has sufficient diagnostic accuracy to stand as a primary diagnostic tool for European house dust mite sensitization.

How Der p 2 Fits Into a Bigger Picture

Der p 2 is not the whole story of mite allergy. Some people react mainly to other mite proteins (Der p 23, Der p 5, 7, 20, or 21), and a meaningful minority of clinically mite allergic patients can be negative for both Der p 1 and Der p 2 while reacting to minor components. That is why most allergy specialists run Der p 2 alongside Der p 1 and, increasingly, Der p 23 to capture the full sensitization pattern.

Tracking Your Trend Over Time

A single Der p 2 IgE reading tells you whether you are sensitized today. It does not tell you whether the underlying allergy is getting better or worse, and it does not predict who will respond best to treatment on its own. Tracking the number over time is far more useful than a one off result.

Allergen immunotherapy is the clearest example. During the first months of treatment, mite specific IgE often rises before it falls. In studies of one to three year subcutaneous immunotherapy courses, Der p 2 IgE tended to drop in clinical responders (one trial saw a median decrease of about 10 kU/L in responders versus a rise of about 6 kU/L in non responders over 12 months), while non responders showed the opposite pattern. Get a baseline, retest at 6 to 12 months if you are starting treatment, and at least annually if you are tracking severity or stability.

What to Do With an Out of Pattern Result

A high Der p 2 IgE in someone with respiratory or skin symptoms is meaningful and should prompt action, not just observation. Consider ordering Der p 1, Der p 23, and total IgE alongside it so you understand the full mite sensitization picture. If you have asthma symptoms, this is a good moment to see an allergist or pulmonologist for spirometry and a discussion about whether immunotherapy makes sense for you.

A positive Der p 2 combined with multiple other mite components is a stronger signal of severe or persistent disease and a stronger argument for a structured treatment plan. A high Der p 2 with no symptoms is less actionable; the test was developed to help interpret existing allergy symptoms, not to screen healthy adults. If your Der p 2 is low but you still have classic mite symptoms, ask about extended component panels (Der p 5, 7, 20, 21, 23) and consider a nasal or skin challenge with extract, since a meaningful share of mite allergic people are negative on Der p 1 and Der p 2 alone.

When Results Can Be Misleading

Mite IgE is a relatively stable lab measurement, but interpretation can still be tripped up:

• Positive result without symptoms: a meaningful share of adults carry detectable mite specific IgE without ever developing clinical allergy. A high Der p 2 IgE only matters in the context of symptoms or planned treatment.
• Recent immunotherapy start: Der p 2 IgE often rises in the first weeks to months of allergen immunotherapy before declining. A higher number at three months does not mean treatment is failing.
• Local allergy: some people have allergic rhinitis driven by IgE produced inside the nasal lining rather than circulating in blood. A negative or low blood Der p 2 IgE does not always rule out local mite driven nasal disease.
• Lab to lab variability: different assay platforms can give different absolute numbers. When comparing readings over time, try to use the same lab and method.

A Note on Certainty

Component resolved diagnostics for dust mite are well established in allergy practice but reference ranges are not universally standardized, and the test is most useful in people who already have suggestive symptoms. The strongest evidence behind Der p 2 IgE is its ability to confirm genuine mite allergy and predict bronchial reactivity. Its role as a long term monitoring tool during immunotherapy is supported by multiple smaller studies but is still being refined.